EGFR and neoplasm: [1, 2] However, patients who initially responded to EGFR-TKIs would eventually present a median of 10–14 months in response evaluation criteria in solid tumors progressive disease (RECIST PD), [3–5] which clinically manifests as tumor progression and symptomatic decline.